Collectively, our studies illustrate the dynamic nature of NRP2 isoform expression in breast cancer and suggest that targeting NPR2 isoform-specific signaling pathways or NRP2-isoform expressing TAM subsets may be leveraged for macrophage reprograming or TAM-targeted immunotherapies. The gene discussed is NPR2; the disease is breast carcinoma.